I've been following (and writing about) Antibe Therapeutics' otenaproxesul, an atypical NSAID without the GI toxicity of Aleve or Advil, since early 2020. It's been nothing but good news. Until now. Otenaproxesul caused a substantial jump in liver enzymes in some clinical trial participants. Can the company overcome this? Wall Street sure doesn't think so.